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Abstract: There are more than 12 new antiepileptic drugs approved in the last 2 decades. 
Even with these newer agents, seizure remission is still unachievable in around 30% of patients 
with partial-onset seizures (POS). Brivaracetam (BRV) is chemically related to levetiracetam 
(LEV) and possesses a strong binding affinity for the synaptic vesicle protein 2A tenfold above 
that of LEV, and other possible modes of antiepileptic actions. BRV is now under Phase III 
development for POS, but data from one Phase III trial also suggested its potential efficacy for 
primary generalized seizures. The purpose of this review is to provide updated information on 
the mechanisms of action of the available antiepileptic drugs, with a focus on BRV to assess 
its pharmacology, pharmacokinetics, clinical efficacy, safety, and tolerability in patients with 
uncontrolled POS. To date, six Phase IIb and III clinical trials have been performed to investigate 
the efficacy, safety, and tolerability of BRV as an adjunctive treatment for patients with POS. 
Generally, BRV was well tolerated and did not show significant difference in safety profile, 
compared to placebo. The efficacy outcomes of BRV, although not consistent across trials, did 
indicate that BRV was a promising add-on therapy for patients with POS. In conclusion, the 
many favorable attributes of BRV, like its high oral efficacy, good tolerability, dosing regi-
men, and minimal drug interaction, make it a promising antiepileptic therapy for patients with 
uncontrolled partial-onset epilepsy.
Keywords: brivaracetam, partial-onset epilepsy, drug-resistant epilepsy, randomized controlled 
trial, review
Introduction
Epilepsy is a chronic neurological disorder characterized by recurrent seizures and 
is estimated to affect approximately 50 million people worldwide.1 Globally, an 
estimated 2.4 million people are diagnosed with epilepsy each year.1 Epilepsy is not 
only associated with detrimental effects on the health and quality of life (QoL) of the 
individual patient, but also places a huge psychological and economic burden on the 
family members of the sufferers. When the diagnosis of epilepsy is established, treat-
ment will be initiated accordingly. The primary treatment objectives are to achieve 
lifelong seizure freedom,2,3 reduce morbidity and mortality, and improve QoL,4 ideally 
without intolerable adverse events (AEs).5 Nonpharmacological management modali-
ties like surgery6 and vagus nerve stimulation7 are available for a selected proportion 
of patients, while the majority of individuals are managed with antiepileptic drugs 
(AEDs). Although the prognosis for the majority of patients is good, up to 30% of cases 
do not show complete remission despite appropriate therapy with AEDs. Normally, 
the AED is selected on the basis of the clinical efficacy, tolerability, drug interaction, 
and ease of use.8 It is reported that most patients could be successfully managed by 
Correspondence: Shuchuen Li
School of Biomedical Sciences and 
Pharmacy, The University of Newcastle, 
MS 108, Medical Sciences Building, 
Callaghan, NSw 2308, Australia
Tel +61 2 4921 5921
Fax +61 2 4921 2044
email shuchuen.li@newcastle.edu.au 
Journal name: Therapeutics and Clinical Risk Management
Article Designation: Review
Year: 2016
Volume: 12
Running head verso: Gao and Li
Running head recto: Review of BRV for partial-onset epilepsy
DOI: http://dx.doi.org/10.2147/TCRM.S90127
Therapeutics and Clinical Risk Management 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
720
Gao and Li
monotherapy alone;8 however, up to 50% still need to be 
treated with combination therapy.9
Monotherapy is the best pharmacotherapeutic option 
when first starting AED treatment.10 If monotherapy is poorly 
tolerated or ineffective, the strategy is to switch to another 
drug; and if the first drug has partial efficacy and is well tol-
erated, it is worthwhile to try another drug in combination.11 
However, add-on therapy has been shown to be more effec-
tive when started immediately after first drug failure rather 
than after a second drug has also failed.12 Nevertheless, when 
adequate trials of two tolerated, appropriately chosen, and 
administered AEDs (whether as monotherapy or in combina-
tion) fail to achieve sustained seizure freedom, a diagnosis of 
drug-resistant epilepsy could be subsequently made.3
Among the two major types of epilepsy, partial-onset 
seizures (POS) occur in more than 60% of patients and 
are the most commonly encountered type of seizure in the 
adult population.13 Often affected by comorbid disorders, 
these patients are difficult to treat, and approximately one-
third of cases are resistant to AED management, including 
combination regimens.14 The introduction of a large num-
ber of newer AEDs with more attractive pharmacokinetic, 
safety, and tolerability profiles over the past 20 years has, 
indeed, increased the treatment options to clinicians, but 
has not had a substantial effect on the seizure remission 
for patients with drug-resistant epilepsy.14 A study assess-
ing seizure freedom rates achieved with the newer AEDs 
including gabapentin, lamotrigine, topiramate, tiagabine, 
oxcarbazepine, levetiracetam (LEV), zonisamide, and 
pregabalin administered as an add-on therapy to patients 
with drug-resistant partial-onset epilepsy showed rather dis-
appointing results.15 Among the included placebo-controlled 
randomized controlled trials (RCTs), the seizure-free rates 
for patients who completed the double-blind phase of the 
trials (between 12 and 21 weeks) ranged from 0.8% to a 
maximum of 7.1%.15 Although another study has reported 
a more promising seizure-free rate over 6 months, as high 
as 14%, with the use of the newer AEDs in real-life clini-
cal practice,16 it is obvious that a considerable proportion 
of patients with epilepsy are inadequately controlled with 
the available AEDs.17
The current review aimed to discuss the emerging and 
current treatment for POS and then focus on the newly 
invented AED, brivaracetam (BRV), with a thorough exami-
nation of its pharmacology, mode of action, pharmacokinet-
ics, comparative safety, efficacy, and tolerability, as well as 
its impact on patient-centered outcomes (eg, QoL, patient 
satisfaction).
Outline of targets for therapy and 
treatments for POS
POS originate from an area of the brain that is abnormally 
hyperexcitable and is intrinsically capable of increased 
abnormal firing of individual neurons.18 This hyperexcitable 
environment is due to the augmentation of excitatory synaptic 
currents mediated by the neurotransmitters glutamate and 
aspartate.18,19 This hyperexcitable state is usually quickly 
terminated by inhibitory currents related to the neurotransmit-
ter gamma-aminobutyric acid (GABA).17 In order to produce 
a seizure, three conditions are needed:19 first, the existence 
of hyperexcitable pacemaker area able to develop intrinsic 
bursts of action potentials that are usually brief and abolished 
by inhibitory mechanisms related to the neurotransmitter 
GABA; second, the absence of inhibition that allows this 
hyperexcitable state in the pacemaker area to be sustained; 
and the third condition is the ability of this pacemaker to 
recruit other brain areas.17 Therefore, the currently marketed 
AEDs or emerging AEDs are targeted at one or more of the 
above-described mechanisms that are engaged in initiating 
and sustaining seizures. It is worth mentioning that LEV 
appears to have a unique mode of action that, at this time, 
remains to be clearly characterized. It is believed to bind to 
a specific, as yet unidentified, site on the synaptic plasma 
membrane.20 The characteristics of the currently available 
AEDs are summarized in Table 1.
AeDs that modulate voltage-gated 
channels
The most common target among AEDs is the sodium channel, 
which is responsible for the upstroke of the action potential in 
neurons and other excitable cells.52 Sodium channel blockade 
is the best characterized mechanism of currently available 
AEDs. These AEDs prevent the return of the channels to 
the active state by stabilizing the inactive form. In doing 
so, repetitive firing of the axons is prevented. Presynaptic 
and postsynaptic blockade of sodium channels of the axons 
causes stabilization of the neuronal membranes, blocks and 
prevents post-tetanic potentiation, limits the development of 
maximal seizure activity, and reduces the spread of seizures. 
Traditional sodium channel blockers include phenytoin, car-
bamazepine (and its derivatives), lamotrigine, and so on.
Another type of voltage-gated channel that AEDs usu-
ally bind is the calcium channel. These AEDs, for example, 
pregabalin and gabapentin, regulate the opening and closing 
of the α
2
δ subunit, thus controlling the entry of calcium ions 
into presynaptic neurons and decreasing the release of various 
presynaptic neurotransmitters.53,54
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One novel ion channel that is targeted by AEDs is the 
neuronal potassium channel. It acts via enhancing the activ-
ity of K
v
7.2/K
v
7.3 potassium channels by binding within 
the pore region.55,56 These channels generate the M current, 
a non-inactivating potassium conductance that regulates the 
neuronal firing rate at a subthreshold voltage between −60 
and −40 mV.57 Enhancing the M current hyperpolarizes the 
cell membrane toward the potassium equilibrium potential.58 
Retigabine (ezogabine) is the AED that falls into this 
category.
AeDs that enhance GABA-related 
inhibitory activity
A seizure reflects an imbalance between excitatory and inhib-
itory activity in the brain, with an increment of excitation over 
inhibition. The most important inhibitory neurotransmitter 
in the brain is GABA. It is the predominant inhibitory neu-
rotransmitter in the central nervous system and is released 
in up to 40% of all synapses.59 Impairment of GABA function 
is widely recognized to provoke seizures, while facilitation 
has an anticonvulsant effect.60 GABA inhibitory activity 
can be achieved via the activation of GABA
A
 receptor 
(phenobarbital), GABA reuptake inhibitor (tiagabine),20 and 
GABA transaminase inhibitor (vigabatrin).20
AeDs that modulate the glutamate-
mediated excitation
Glutamate is the principal excitatory neurotransmitter in 
the mammalian brain. Focal injection of glutamate induces 
seizures in animals, and overactivation of glutamatergic 
transmission or abnormal glutamate receptor properties are 
observed in certain experimental seizure models and human 
epilepsy syndrome. A new AED (perampanel) has a new 
well-defined mechanism of action by selectively modulat-
ing excitatory glutamatergic transmission via modulation 
of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor.
AeDs that have multiple mechanisms 
of action
Some AEDs may invoke multiple mechanisms of action 
to exert their anticonvulsive effects. Valproate, a broad-
spectrum AED, is reported to block voltage-dependent 
sodium channel,20 T-type calcium channel,61 and may elevate 
whole brain GABA levels and potentiate GABA response.60 
Topiramate may be involved in the inhibition of sodium 
and calcium currents, blockade of the α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid/kainite subtype of 
glutamate receptor, and facilitation of GABA effects at the 
GABA
A
 receptor.20 Zonisamide could act through blocking 
the voltage-gated sodium channel, inhibiting T-type calcium 
channels,62–64 and enhancing GABA release and inhibiting 
glutamate release.62,64 Felbamate is believed to be the first 
effective AED with a direct action on the N-methyl-d-
aspartate (NMDA) subtype of glutamate receptor,20 and it 
also inhibits NMDA/glycine-stimulated increases in intracel-
lular calcium,65 reduces inward currents evoked by NMDA 
application to striatal neurons,66 and blocks NMDA receptor-
mediated excitatory postsynaptic potentials.67
Brivaracetam
Pharmacology
Mode of action
Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein 
common to all synaptic and endocrine vesicles. The synaptic 
vesicle protein 2A (SV2A), the primary SV2 isoform, is a 
widely distributed central nervous system protein, and is 
believed to participate in the coordination of synaptic vesicle 
exocytosis and neurotransmitter release.68 This is shown by 
the observation that SV2A knockout mice develop seizures, 
which leads to their demise within the first few weeks.68 
In contrast, while heterozygous SV2A knockout mice do 
not demonstrate spontaneous seizures, they exhibit enhanced 
susceptibility to the convulsant effect of pilocarpine and 
kainite, a reduced 6 Hz seizure threshold, and an enhanced 
rate of seizure kindling.69
LEV is thought to exert its main action at a specific bind-
ing site – the presynaptically located SV2A, which modulates 
presynaptic transmitter release.70 BRV is a highly selective 
and reversible SV2A ligand with a 15- to 30-fold higher 
affinity than LEV in rat and human brain.71,72 The increased 
binding affinity of BRV, compared to LEV, to the presyn-
aptically located SV2A corresponds to a higher efficacy in 
the animal models.73 In addition to this, the modulation of 
SV2A function by BRV is also believed to contribute to its 
anticonvulsant effect. Besides, BRV also displays inhibitory 
activity at neuronal voltage-dependent sodium channels.74 
At any rate, the sodium channel modulation represents a 
distinct activity of BRV compared with LEV.75 Furthermore, 
compared to LEV, BRV is able to inhibit NMDA-gated 
currents by up to one third.74 All these modes of action may 
be associated with the wider spectrum of anticonvulsant 
mechanism of BRV.
The activity of BRV was studied in both focal and 
generalized seizure models. In the amygdala-kindled rat, 
BRV produced a more profound suppression of both motor 
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seizure severity and after-discharge duration than LEV.76 
In mice genetically susceptible to audiogenic seizures, 
BRV offered more potent protection from clonic convul-
sions than LEV, while in the Genetic Absence Epilepsy Rat 
from Strasbourg, it exerted a more complete suppression 
of spike–wave discharge than LEV.77 The anticonvulsant 
properties of BRV were also investigated in a partially 
drug-resistant self-sustaining status epilepticus rat model. 
The combination of diazepam and BRV was able to reduce 
the duration of active seizures to 3% of controls, which 
indicated potent anticonvulsant activity of the compound 
in status epilepticus.78
Pharmacokinetics
BRV is rapidly absorbed after oral administration, with a 
t
max 
around 1 hour (ranging from 0.5 to 1.75 hours) and C
max
 
between 10 and 1,400 mg, when applied in a single dose.76 
However, a high fat meal is likely to delay t
max
 to 3 hours 
and decrease C
max 
by about 28%.79 BRV has a linear fashion 
of pharmacokinetics over a dose range from 10 to 600 mg. 
It was evenly absorbed throughout the gastrointestinal tract, 
as evidenced by the relative area under the curve (AUC) 
(100% = stomach) of 101%, 98%, and 97% following deliv-
ery in the proximal jejunum, distal jejunum, and ascending 
colon, respectively.76 The metabolic clearance of BRV is 
increased in a time-dependent manner at supratherapeutic 
doses and a steady state is reached within a week of repeated 
administration.76 The terminal elimination half-life of BRV 
is approximately 8 hours and does not vary with the applied 
doses.80 Its protein binding is low with a volume of distribu-
tion of 0.6 L/kg, marginally lower than total body water.79,81 
The primary metabolic pathways of BRV include hepatic 
hydrolysis of the acetamide group, CYP2C8-mediated 
hydroxylation, and a combination of these pathways,76 mainly 
by the CYPSC8 isoform of cytochrome P450 (CYP450) 
and, to a lesser degree, by the isoforms CYP3A4 and 
CYP2C19,82 but all metabolites in the human urine (2-[2-oxo-
4-propylpyrrolidin-1-yl]butyric acid (35%) and 2-[2-oxo-4-
propylpyrrolidin-1-yl]-4-hydroxy-butanamide [,10%]) are 
not pharmacologically active.79 Its elimination is reliant on 
metabolism, largely via the activity of CYP450 system; thus, 
the renal clearance of the parent drug is low at 0.06 mL/min/kg 
(whereas the metabolites have a high renal clearance). It was 
reported that in patients with chronic liver disease, total body 
clearance of BRV may be reduced by 25%–35% and plasma 
half-life is accordingly prolonged to 14–17 hours,76 while no 
major adjustment in dosage is required in patients with severe 
renal impairment without dialysis.83
Pharmacodynamics
Studies in healthy volunteers showed that in high-dose 
range, BRV was associated with dose-related sedation and 
decreased alertness.79,81 For subjects on 200, 400, 800 mg 
daily and placebo, the mean (standard deviation) AUC 
change from baseline (ΔAUC
0–12 hours
) on day 7 was 6 (13), 12 
(42), 17 (21), and 3 (9), respectively, for the Pentobarbital–
Chlorpromazine–Alcohol Group subscale of the Addictive 
Research Centre Inventory-49 questionnaire (it measures 
sedative drug effects). The mean (standard deviation) 
ΔAUC
0–12 hours 
of the
 
visual analog scale (VAS), an alertness 
scale with higher value indicative of reduced alertness, was 
5 (22), 46 (109), 57 (95), and −2 (26), respectively, while no 
trends of changes on the calmness VAS scale, ataxia (Inter-
national Cooperative Ataxia Rating Scale Examination), or 
other neurological examinations were observed.79,81
The potential pharmacodynamic interaction between 
alcohol and BRV was also investigated. Coadministration 
of BRV and ethanol in healthy subjects was associated with 
additive effects on most of the pharmacodynamic variables 
(eg, saccadic peak velocity, smooth pursuit, adaptive tracking 
performance, and VAS alertness) without relevant pharma-
cokinetic interaction between BRV and ethanol.84
Comparative safety, efficacy, and 
tolerability of BRv
Safety and tolerability
Generally, all studies did not report statistically significant 
difference between BRV and placebo groups in terms of 
treatment-emergent adverse events (TEAEs).85–89 Further-
more, no evident trend was observed in the incidence of 
TEAEs across all doses of BRV. The most commonly 
reported TEAEs were dizziness, headache, nasopharyngitis, 
nausea, fatigue, and somnolence from mild to moder-
ate intensity. The TEAEs reported by greater than 5% of 
patients during the treatment period in each trial are shown 
in Table 2. A visual inspection of the incidence of TEAE 
identified that dizziness, somnolence, and influenza more 
frequently occurred in the BRV-treated group regardless of 
the doses administered.88 The meta-analysis of five BRV 
trials also identified no statistically significant association 
between the administration of BRV and the majority of 
safety endpoints, including at least one TEAE, drug-related 
TEAEs, and serious adverse events.90 However, in terms of 
individual TEAEs, another pooled analysis reported a sig-
nificant difference between 20 mg BRV and placebo in the 
incidences of fatigue and nasopharyngitis (relative risk [RR]: 
3.00 [95% confidence interval {CI}: 1.20–7.47] and 5.98 
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[95% CI: 1.36–26.34], respectively). Moreover, increased 
incidence of fatigue and irritability was also detected in the 
50 mg BRV group compared to placebo (RR: 2.38 [95% 
CI: 1.16–4.88] and 2.95 [95% CI: 1.03–8.44], respectively). 
In addition, the risk of somnolence was significantly differ-
ent between 150 mg BRV and placebo groups (RR: 2.21 
[95% CI: 1.02–4.80]), while no significant differences were 
observed for either dose of 5 or 100 mg with respect to the 
TEAEs recorded in individual studies.91
Regarding treatment discontinuation, patients withdrew 
from each trial due to AEs, lack of efficacy, loss to follow-up, 
and withdrawal of consent due to personal reasons. However, 
all the RCTs did not show remarkable distinctions in with-
drawal rates between BRV and placebo groups (Table 3). 
Nevertheless, the majority of discontinuation was accounted 
for by AEs caused by either BRV or concomitant AEDs. The 
results of meta-analysis on the overall withdrawal rate also 
indicated no statistical difference between BRV and placebo 
groups (RR: 1.08, 95% CI: 0.73–1.59; P=0.70).90 The reason 
for withdrawal as assessed by another meta-analysis also 
showed consistent and similar results.91
Besides, the effects of BRV on cardiac repolarization 
and neurocognition were studied in healthy subjects. It was 
found that the QT interval did not increase with plasma 
concentration of BRV,92 and BRV did not alter the profile 
of cognitive, subjective, and electrophysiologic effects, 
compared to placebo.93
Efficacy
To date, six RCTs have reported the efficacy outcomes of 
various doses of BRV as adjunctive treatment in a population 
of patients with partial-onset epilepsies.85–89,94 The percentage 
reduction in baseline-adjusted POS frequency/week85–89 (or 
28 days)94 over placebo was adopted as the primary efficacy 
outcome across all RCTs, while the responder rate (defined 
as the percentage of patients who achieved 50% reduction 
in seizure frequency compared to baseline) was employed 
as the secondary efficacy outcome. In general, higher dose 
of BRV is likely to produce significant efficacy outcome, 
compared to placebo. Among these studies, a Phase IIb 
trial86 and a Phase III trial89 failed to detect a significant 
difference in the primary efficacy outcome, while in the 
other four RCTs, 50 mg/day85,87,88 or 100 and 200 mg/day94 
of BRV was found to be more effective than placebo in 
achieving the primary efficacy outcome. The percentage 
reduction in baseline-adjusted POS frequency/week ranged 
from −0.9%88 to 22.1%85 across all the doses. In comparison, 
a recently published study on two higher doses of BRV (100 
and 200 mg/day) reported the most promising outcomes.94 
The reduction in baseline-adjusted POS frequency/28 days 
over placebo was 22.8% (P,0.001) and 23.2% (P,0.001) 
for BRV 100 and 200 mg/day, respectively. Regarding the 
rate of responders, more studies reported significant differ-
ence for this outcome (Table 4). Nevertheless, the lower 
doses (ie, 5 and 20 mg/day) used in three RCTs did not 
show any statistical difference between BRV and placebo 
in the primary efficacy endpoint. Figures 1 and 2 summarize 
the $50% responder and seizure-free rates across all the 
RCTs of BRV.
Two meta-analyses90,91 that synthesized the results of 
responder rate and seizure-free rate yielded similar results 
across all doses of BRV from five RCTs.85–89 In a fixed-effects 
model, the responder rate was significantly higher in BRV 
group compared with placebo group for doses of 20 mg/day 
(RR: 1.63, 95% CI: 1.18–2.27; P=0.003), 50 mg/day (RR: 
2.00, 95% CI: 1.50–2.66; P,0.001), and 100 mg/day (RR: 
1.80, 95% CI: 1.12–2.88; P=0.01).90 Whereas, regarding 
seizure-free rate reported in three RCTs,85,86,88 significant 
difference was detected for the dose of 50 mg/day (RR: 5.80, 
95% CI: 1.54–21.84; P=0.009) in only one meta-analysis.90 
However, it is worth noting that the seizure-free rate was 
defined as free from POS in two of those three studies.85,86
Patient profiles
Patients with similar epilepsy-specific and demographic 
characteristics were studied in the six Phase IIb and III RCTs. 
For recruitment, patients were required to experience at least 
four85,86,89 or eight 87,88 POS, depending on the length of the 
baseline period. However, the inclusion criteria across the 
studies varied slightly: the latest Phase III RCT enrolled sub-
jects with the widest age range (16–80 years old)94 and three 
other RCTs recruited patients aged between 16 and 70 years, 
while subjects recruited in the two Phase IIb trials had the 
narrowest age range (16–65 years old).87–89 It was reported 
that compared to middle-aged patients with epilepsy, elderly 
patients were more likely to respond favorably to treatment 
even at lower doses.95 In fact, other studies have also shown 
better treatment outcome in elderly patients with epilepsy.96,97 
This may give rise to heterogeneity in the study population 
across RCTs. With regard to the concomitant AEDs, except 
for the study by Kwan et al89 (with one to three AEDs allowed 
during the study period), only one or two concomitant AEDs 
were allowed in all the trials. This may lead to the enrollment 
of patients with varied levels of uncontrolled POS. Of note, 
the number of prior AEDs used by patients in the past 5 years 
in the reported trials varied substantially as well. For instance, 
in the study by Van Paesschen et al,86 34.6%–45.3% of 
patients had taken and discontinued $5 AEDs during the past 
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Table 4 Characteristics and primary results of key RCTs for brivaracetam
Study ITT 
(according 
to dosage)
Age Sex 
(male %)
Duration 
of disease 
(years)
Treatment period Number of  
concomitant AEDs
Seizure types Percentage 
reduction 
in seizure 
frequency/week 
over placebo§
Responder 
rate (%)§
Seizure-free 
rate (%)¶
Any TEAE 
(%)*
Drug-
related 
TEAEs
SAEs
1 2 $3 Simple 
partial 
Complex 
partial
Complex 
partial with SG
French 2010/119385 n=50
5 mg/day
32.7 (12.2) 60.0 16.0 (11.5) 4 weeks baseline
7 weeks treatment
30.0 58.0 12.0 36.0 90.0 74.0 9.8
P=0.240
32.0
(P=0.047)
8.0 52.0 14.0 4.0
n=52
20 mg/day
35.3 (13.7) 53.8 22.9 (13.5) 42.3 53.8 3.8 30.8 86.5 75.0 14.9
P=0.062
44.2
(P=0.002)
7.7 55.8 19.2 0
n=52
50 mg/day
30.9 (11.6) 53.8 19.1 (10.8) 30.8 65.4 3.8 30.8 82.7 55.8 22.1
P=0.004
55.8
(P,0.001)
7.7 53.8 23.1 0
n=54
Placebo
33.6 (11.3) 44.4 21.7 (13.0) 37.0 57.4 5.6 44.4 83.3 53.7 – 16.7 1.9 53.7 22.2 3.7
van Paesschen 2013/111486 n=53
50 mg/day
38.2 (12.1) 45.3 25.1 (14.8) 4 weeks baseline
3 weeks up-titration
7 weeks maintenance
24.5 66.0 9.4 50.9 96.2 75.5 14.7
P=0.093
39.6
(P=0.077)
9.4 67.9 41.5 1.9
n=52
150 mg/day
34.4 (10.1) 40.4 19.8 (11.6) 17.3 75.0 7.7 46.2 92.3 71.2 13.6
P=0.124
33.3
(P=0.261)
5.8 67.3 36.5 3.8
n=52
Placebo 
40.0 (11.7) 48.1 21.0 (12.9) 13.5 82.7 1.9 42.3 82.7 69.2 – 23.1 1.9 71.2 42.3 7.7
Ryvlin 2014/125287 n=99
5 mg/day
35.7 (12.5) 61.6 22.1 (13.6) 8 weeks baseline
12 weeks treatment
18.2 77.8 4.0 NR NR NR 6.8
P=0.239
27.3
(P=0.339)
2.0 56.6 23.2 1.0
n=99
20 mg/day
38.9 (13.6) 54.5 22.3 (13.0) 20.2 77.8 2.0 NR NR NR 6.5
P=0.261
27.3
(P=0.372)
0 62.6 37.4 4.0
n=100
50 mg/day
38.0 (13.1) 58.0 22.1 (12.8) 16.0 77.0 7.0 NR NR NR 11.7
P=0.037
36.0
(P=0.023)
4.0 63.0 42.0 2.0
n=100
Placebo
36.4 (13.0) 54.0 20.4 (12.3) 14.0 83.0 3.0 NR NR NR – 30.0 0 53.0 31.0 6.0
Biton 2014/125388 n=97
5 mg/day
38.9 (11.6) 50.5 22.2 (12.1) 8 weeks baseline
12 weeks treatment
14.4 78.4 7.2 NR NR NR −0.9
P=0.885
21.9
(P=0.353)
1.1 71.1 44.3 8.2
n=100
20 mg/day
37.3 (13.3) 52.0 22.9 (14.0) 16.0 72.0 12.0 NR NR NR 4.1
P=0.492
23.2
(P=0.239)
1.0 79.0 46.0 4.0
n=101
50 mg/day
38.9 (12.3) 50.5 26.2 (12.0) 12.9 81.2 5.9 NR NR NR 12.8
P=0.025
32.7
(P=0.008)
4.0 75.2 55.4 8.9
n=98
Placebo
37.5 (12.6) 43.9 24.3 (12.2) 13.3 81.6 4.1 NR NR NR – 16.7 0 NR 35.7 5.1
Kwan‡ 2014/125489 n=323
150Max mg/day
36.4 (11.5) 50.8 21.8 (12.5) 4 weeks baseline
8 weeks up-titration
8 weeks maintenance
14.6 49.2 36.2 36.5 82.4 66.6 7.3
P=0.125
30.3
(P=0.006)
1.5 66.0 NR 5.3
n=108
Placebo
36.6 (11.9) 55.6 22.1 (11.7) 19.4 36.1 44.4 35.2 81.5 73.1 – 16.7 0 65.3 NR 7.4
Klein (abstract)
2015/NCT0126132594
100 mg/day 39.5 (12.9) 48.2 22.8 8 weeks baseline
12 weeks treatment
NR NR NR NR NR NR 22.8&
P,0.001
38.9
(P,0.001)
5.2 68.4 NR NR
200 mg/day NR NR NR NR NR NR 23.2&
P,0.001
37.8
(P,0.001)
4.0 66.8 NR NR
Placebo NR NR NR NR NR NR – 21.6 0.8 59.4 NR NR
Notes: *it was for the entire treatment period (titration + maintenance period). §For these two outcomes, in the studies by French et al,85 Ryvlin et al,87 and Biton et al,88 they 
were for treatment period; in the study by van Paesschen et al,86 they were for maintenance period only. ¶in the studies by French et al85 and van Paesschen et al,86 seizure 
free was defined as free of partial-onset seizure during the treatment period, while in the other three studies, it was defined as seizure free of any type of seizures. ‡Only the 
results from patients with partial-onset seizures were presented. &This is the percentage reduction over placebo in 28 days.
Abbreviations: AeDs, antiepileptic drugs; iTT, intention-to-treat; NR, not reported; RCT, randomized controlled trial; SG, secondary generalization; TeAe, treatment-
emergent adverse events; SAes, serious adverse events.
5 years compared to 2.0%–7.0% in the study by Ryvlin et al.87 
It has been demonstrated that the rates of seizure freedom 
and patients with a .50% seizure frequency reduction 
after administration of new AED decrease as a function of 
the number of previously failed AEDs.98 So, this would be 
another source of heterogeneity in patient characteristics 
among trials. Nonetheless, from two meta-analyses,90,91 the 
statistical measures (χ2 and I2) did not show considerable 
heterogeneities across the included RCTs for outcomes such 
as responder rate and seizure-free rate. This might suggest 
that the aforementioned differences in the study populations 
were not significant in producing heterogeneity.
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Table 4 Characteristics and primary results of key RCTs for brivaracetam
Study ITT 
(according 
to dosage)
Age Sex 
(male %)
Duration 
of disease 
(years)
Treatment period Number of  
concomitant AEDs
Seizure types Percentage 
reduction 
in seizure 
frequency/week 
over placebo§
Responder 
rate (%)§
Seizure-free 
rate (%)¶
Any TEAE 
(%)*
Drug-
related 
TEAEs
SAEs
1 2 $3 Simple 
partial 
Complex 
partial
Complex 
partial with SG
French 2010/119385 n=50
5 mg/day
32.7 (12.2) 60.0 16.0 (11.5) 4 weeks baseline
7 weeks treatment
30.0 58.0 12.0 36.0 90.0 74.0 9.8
P=0.240
32.0
(P=0.047)
8.0 52.0 14.0 4.0
n=52
20 mg/day
35.3 (13.7) 53.8 22.9 (13.5) 42.3 53.8 3.8 30.8 86.5 75.0 14.9
P=0.062
44.2
(P=0.002)
7.7 55.8 19.2 0
n=52
50 mg/day
30.9 (11.6) 53.8 19.1 (10.8) 30.8 65.4 3.8 30.8 82.7 55.8 22.1
P=0.004
55.8
(P,0.001)
7.7 53.8 23.1 0
n=54
Placebo
33.6 (11.3) 44.4 21.7 (13.0) 37.0 57.4 5.6 44.4 83.3 53.7 – 16.7 1.9 53.7 22.2 3.7
van Paesschen 2013/111486 n=53
50 mg/day
38.2 (12.1) 45.3 25.1 (14.8) 4 weeks baseline
3 weeks up-titration
7 weeks maintenance
24.5 66.0 9.4 50.9 96.2 75.5 14.7
P=0.093
39.6
(P=0.077)
9.4 67.9 41.5 1.9
n=52
150 mg/day
34.4 (10.1) 40.4 19.8 (11.6) 17.3 75.0 7.7 46.2 92.3 71.2 13.6
P=0.124
33.3
(P=0.261)
5.8 67.3 36.5 3.8
n=52
Placebo 
40.0 (11.7) 48.1 21.0 (12.9) 13.5 82.7 1.9 42.3 82.7 69.2 – 23.1 1.9 71.2 42.3 7.7
Ryvlin 2014/125287 n=99
5 mg/day
35.7 (12.5) 61.6 22.1 (13.6) 8 weeks baseline
12 weeks treatment
18.2 77.8 4.0 NR NR NR 6.8
P=0.239
27.3
(P=0.339)
2.0 56.6 23.2 1.0
n=99
20 mg/day
38.9 (13.6) 54.5 22.3 (13.0) 20.2 77.8 2.0 NR NR NR 6.5
P=0.261
27.3
(P=0.372)
0 62.6 37.4 4.0
n=100
50 mg/day
38.0 (13.1) 58.0 22.1 (12.8) 16.0 77.0 7.0 NR NR NR 11.7
P=0.037
36.0
(P=0.023)
4.0 63.0 42.0 2.0
n=100
Placebo
36.4 (13.0) 54.0 20.4 (12.3) 14.0 83.0 3.0 NR NR NR – 30.0 0 53.0 31.0 6.0
Biton 2014/125388 n=97
5 mg/day
38.9 (11.6) 50.5 22.2 (12.1) 8 weeks baseline
12 weeks treatment
14.4 78.4 7.2 NR NR NR −0.9
P=0.885
21.9
(P=0.353)
1.1 71.1 44.3 8.2
n=100
20 mg/day
37.3 (13.3) 52.0 22.9 (14.0) 16.0 72.0 12.0 NR NR NR 4.1
P=0.492
23.2
(P=0.239)
1.0 79.0 46.0 4.0
n=101
50 mg/day
38.9 (12.3) 50.5 26.2 (12.0) 12.9 81.2 5.9 NR NR NR 12.8
P=0.025
32.7
(P=0.008)
4.0 75.2 55.4 8.9
n=98
Placebo
37.5 (12.6) 43.9 24.3 (12.2) 13.3 81.6 4.1 NR NR NR – 16.7 0 NR 35.7 5.1
Kwan‡ 2014/125489 n=323
150Max mg/day
36.4 (11.5) 50.8 21.8 (12.5) 4 weeks baseline
8 weeks up-titration
8 weeks maintenance
14.6 49.2 36.2 36.5 82.4 66.6 7.3
P=0.125
30.3
(P=0.006)
1.5 66.0 NR 5.3
n=108
Placebo
36.6 (11.9) 55.6 22.1 (11.7) 19.4 36.1 44.4 35.2 81.5 73.1 – 16.7 0 65.3 NR 7.4
Klein (abstract)
2015/NCT0126132594
100 mg/day 39.5 (12.9) 48.2 22.8 8 weeks baseline
12 weeks treatment
NR NR NR NR NR NR 22.8&
P,0.001
38.9
(P,0.001)
5.2 68.4 NR NR
200 mg/day NR NR NR NR NR NR 23.2&
P,0.001
37.8
(P,0.001)
4.0 66.8 NR NR
Placebo NR NR NR NR NR NR – 21.6 0.8 59.4 NR NR
Notes: *it was for the entire treatment period (titration + maintenance period). §For these two outcomes, in the studies by French et al,85 Ryvlin et al,87 and Biton et al,88 they 
were for treatment period; in the study by van Paesschen et al,86 they were for maintenance period only. ¶in the studies by French et al85 and van Paesschen et al,86 seizure 
free was defined as free of partial-onset seizure during the treatment period, while in the other three studies, it was defined as seizure free of any type of seizures. ‡Only the 
results from patients with partial-onset seizures were presented. &This is the percentage reduction over placebo in 28 days.
Abbreviations: AeDs, antiepileptic drugs; iTT, intention-to-treat; NR, not reported; RCT, randomized controlled trial; SG, secondary generalization; TeAe, treatment-
emergent adverse events; SAes, serious adverse events.
Patient-reported outcomes
Epilepsy, as a chronic disorder, has considerable negative 
effect on people’s day-to-day functioning. Meanwhile, sei-
zures are still poorly controlled in around 30% of patients, 
even with multiple antiepileptic therapies. For these patients, 
traditional clinical outcomes that measure the treatment effect, 
such as seizure frequency, seizure-free days, and responder 
rate, might not be sufficient to capture all the benefits gen-
erated by treatment and are also incapable of reflecting the 
total impact of epilepsy on patient’s well-being and their own 
perception of treatment effect. Consequently, an increasing 
number of RCTs integrated the measurement of QoL of 
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Figure 1 Responder rates of $50% in the RCTs of BRv.
Abbreviations: BRv, brivaracetam; PBO, placebo; RCT, randomized controlled trial.
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Figure 2 Seizure-free rates in the RCTs of BRv.
Abbreviations: BRv, brivaracetam; PBO, placebo; RCT, randomized controlled trial.
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patients into the design of epilepsy trials to provide a more 
holistic evaluation of treatment effects and adverse effects of 
newly invented AEDs. To date, the QoL in patients with POS 
administered BRV has not been reported. Instead, the only 
study in patients with genetically ascertained Unverricht–
Lundborg disease with action myoclonus reported a signifi-
cant improvement in QoL as measured by Quality of Life in 
Epilepsy-30 at BRV 50 and 150 mg/day, despite its statisti-
cally significant effect on action myoclonus.99
At the time of this review, three Phase III, open-label, 
multicenter, flexible-dose (up to a maximum dose of 
150 mg/day), long-term follow-up trials (NO1125, 
NCT00175916; NO1199, NCT00150800; and NO1315, 
NCT00761774) are still ongoing to evaluate the long-term 
safety/tolerability and maintenance of efficacy of BRV in 
patients with POS who had participated in previous trials. 
Although the proportion of patients from the BRV group who 
entered into the open phase of the individual trials did not 
generally show a favorable trend compared to the placebo 
group, a meta-analysis of trials of adjunctive AEDs in adults 
with drug-resistant focal epilepsy found the responder rates 
to placebo virtually double between 1989 and 2009.100 This 
may partially explain the unnoticeable difference between 
BRV and placebo groups. Anyway, when the results from 
those trials are released, a more comprehensive picture of 
BRV may become available.
Conclusion
Monotherapy is the first step to try for all patients with newly 
diagnosed epilepsy. Following an ineffective or intolerable 
initial monotherapy, the next step is to add or switch to another 
AED. Evidence has indicated that add-on therapy might be 
more effective when started immediately after the first drug 
failure rather than after a second drug has also failed.12 After 
failing to achieve sustained seizure freedom with two toler-
ated, appropriately chosen and administered AEDs (regard-
less of monotherapy or multitherapy) in a patient,3 the patient 
could be classified as having drug-resistant epilepsy. When 
add-on therapy is warranted (for those who either failed the 
first monotherapy or have drug-resistant epilepsy), seizure 
characteristics, drug and patient factors become an important 
consideration when implementing the management strat-
egies.101 Selection of an AED is usually made based on the 
seizure type, spectrum of activity, tolerability, drug interac-
tion, and patient’s personal circumstances.101
Similar to all the other newer generations of AEDs, BRV 
has been investigated as an adjunctive therapy for adult 
patients with uncontrolled partial-onset epilepsies (and in 
very limited number of patients with generalized epilep-
sies89). So far, BRV appears to be a useful new addition to 
adjunctive treatment option for partial-onset epilepsy, par-
ticularly for patients who had not achieved adequate seizure 
control with one or more other adjunctive therapies.85,87,88,94 
In general, the newer group of AEDs has been associated with 
better safety and tolerability, fewer AEs, and improved QoL, 
compared with more traditional agents. However, with no 
direct head-to-head comparison among these newly invented 
drugs, it is extremely difficult for clinicians to choose from a 
dozen of these newer agents. It was even reported that clini-
cians often choose therapy according to their own comfort 
level with the particular AEDs, rather than weighing up all 
disadvantages and advantages of older versus newer, less-
familiar drugs.8 Hence, drugs with simpler dosing regimens 
and uncomplicated titration schedules, undoubtedly, have 
an advantage. BRV, with a twice-daily dosing regimen and 
well tolerated by patients even at a dose of 200 mg/day 
without up-titration, would be an attractive option.94 But 
when LEV and BRV are compared, given the similarity in 
chemical structure and possible pharmacology between them, 
the choice is more complicated. The relationship between 
primary efficacy outcome in BRV pivotal trials and history 
of LEV administration (prior LEV, concomitant LEV, and 
LEV-naïve) was explored.88 Of interest, LEV-naïve patients 
and those with prior LEV histories achieved numerically 
(though statistically not significant) greater reduction in sei-
zure frequency compared to placebo,85,86,88 while concomitant 
LEV might reduce the efficacy of BRV.
As BRV is still under review by different regulatory 
agencies (including US Food and Drug Administration and 
European Medicines Agency) for the treatment of POS in 
patients of age 16 years and above with epilepsy, no data 
about its use in real-life clinical practice is available at the 
moment. Meanwhile, it has gained an orphan drug status 
for development in progressive and symptomatic myoclonic 
seizures in Europe and US, respectively.102 In summary, the 
many favorable attributes of BRV, like its high oral efficacy, 
good tolerability, dosing regimen, and minimal drug inter-
action, make it a promising antiepileptic choice for patients 
with uncontrolled partial-onset epilepsy.
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